Table of Contents

doi : 10.1016/S0923-7534(25)06222-2

Volume 36, Issue 12, December 2025, Pages i-ii

خرید پکیج و مشاهده آنلاین مقاله

Editorial Board

doi : 10.1016/S0923-7534(25)06223-4

خرید پکیج و مشاهده آنلاین مقاله

The East and West consolidated efficacy of radioligand therapy in neuroendocrine tumors

doi : 10.1016/j.annonc.2025.09.015

خرید پکیج و مشاهده آنلاین مقاله

Targeting the epigenome and immune evasion: a new chapter in PRMT5 inhibition

doi : 10.1016/j.annonc.2025.09.014

خرید پکیج و مشاهده آنلاین مقاله

Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer

doi : 10.1016/j.annonc.2025.09.007

خرید پکیج و مشاهده آنلاین مقاله

ESMO guidance on the use of Large Language Models in Clinical Practice (ELCAP)

doi : 10.1016/j.annonc.2025.09.001

خرید پکیج و مشاهده آنلاین مقاله

177Lu-Dotatate versus high-dose long-acting octreotide for the treatment of patients with advanced, grade 1-2, well-differentiated gastroenteropancreatic neuroendocrine tumours (XT-XTR008-3-01): an open-label, randomised, phase III trial☆

doi : 10.1016/j.annonc.2025.08.3758

خرید پکیج و مشاهده آنلاین مقاله

Effect of 5 years of CT-scan and CEA follow-up on survival endpoints in patients with colorectal cancer: the PRODIGE-13 FFCD phase III trial

doi : 10.1016/j.annonc.2025.09.004

خرید پکیج و مشاهده آنلاین مقاله

Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers

doi : 10.1016/j.annonc.2025.08.3757

خرید پکیج و مشاهده آنلاین مقاله

A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients

doi : 10.1016/j.annonc.2025.08.005

خرید پکیج و مشاهده آنلاین مقاله

Dostarlimab and niraparib in primary advanced ovarian cancer

doi : 10.1016/j.annonc.2025.05.009

خرید پکیج و مشاهده آنلاین مقاله

Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical cancer following radical hysterectomy and lymphadenectomy: results from NRG Oncology/GOG-263/KGOG 1008☆

doi : 10.1016/j.annonc.2025.09.003

خرید پکیج و مشاهده آنلاین مقاله

Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma

doi : 10.1016/j.annonc.2025.08.007

خرید پکیج و مشاهده آنلاین مقاله

Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma☆

doi : 10.1016/j.annonc.2025.08.008

خرید پکیج و مشاهده آنلاین مقاله

A temporal paradox in the proposed risk-adjusted surveillance algorithm for metastatic colorectal cancer

doi : 10.1016/j.annonc.2025.09.013

خرید پکیج و مشاهده آنلاین مقاله

Response to ‘A temporal paradox in the proposed risk-adjusted surveillance algorithm for metastatic colorectal cancer’

doi : 10.1016/j.annonc.2025.09.016

خرید پکیج و مشاهده آنلاین مقاله

Larcher et al. The OpeRa trial: the active role of the patient in the clinical decision-making process and surgical planning

doi : 10.1016/j.annonc.2025.09.011

خرید پکیج و مشاهده آنلاین مقاله

An unforeseen, existential threat to oncological research in Europe

doi : 10.1016/j.annonc.2025.09.009

خرید پکیج و مشاهده آنلاین مقاله

Mechanism-enhanced population science: strengthening population studies through functional insights

doi : 10.1016/j.annonc.2025.08.006

خرید پکیج و مشاهده آنلاین مقاله

SUNNIFORECAST trial design supported by real-world data in papillary renal cell carcinoma

doi : 10.1016/j.annonc.2025.09.012

خرید پکیج و مشاهده آنلاین مقاله

Corrigendum to “Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3�: [Ann Oncol 2024; 35: 718-727]

doi : 10.1016/j.annonc.2025.07.002

خرید پکیج و مشاهده آنلاین مقاله

Corrigendum to “Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)�: [Ann Oncol 26 (2015) 2168–2173]

doi : 10.1016/j.annonc.2025.07.011

خرید پکیج و مشاهده آنلاین مقاله

Corrigendum to “Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II population�: [Ann Oncol 36 (2025) 520-528]

doi : 10.1016/j.annonc.2025.09.005

خرید پکیج و مشاهده آنلاین مقاله